Travere Therapeutics, Inc. (TVTX)

NGM – Real Time Price. Currency in USD

61.99

+1.78 (2.96%)

Market open: Aug 12, 2026, 3:24 PM EDT

60.21

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

491M

233M

145M

109M

Cost of goods sold

-71M

-51M

-50M

-25M

Gross Profit

420M

182M

95M

84M

Operating expenses (excl. COGS)

-482M

-438M

-472M

-404M

Operating Income

-63M

-256M

-377M

-320M

Non-operating income, total

14M

-64M

634K

-11M

Pretax income

-49M

-321M

-376M

-331M

Equity in earnings

Taxes

-988K

-120K

-223K

-313K

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

-50M

-321M

-376M

-331M

Discontinued operations

-915K

39M

53M

Net income

-50M

-322M

-337M

-278M

Dilution adjustment

Preferred dividends

Travere Therapeutics, Inc. (TVTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Travere Therapeutics, Inc. (TVTX)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Travere Therapeutics, Inc. (TVTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Travere Therapeutics, Inc. (TVTX)

Income Statement (Annual)

Income Statement (Annual)